Announcements Trials
Browse Landscape

Phase

Phase NA 8Phase 2 2Phase 2/3 1

Status

Recruiting 2

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 227Carcinoma, Non-Small-Cell Lung 220Prostatic Neoplasms 156Multiple Myeloma 142Neoplasms 134Colorectal Neoplasms 118Leukemia, Myeloid, Acute 109Lung Neoplasms 103Neoplasm Metastasis 99Squamous Cell Carcinoma of Head and Neck 93Carcinoma, Hepatocellular 85Lymphoma 80Melanoma 77Pancreatic Neoplasms 73Triple Negative Breast Neoplasms 72Ovarian Neoplasms 71Sarcoma 66Lymphoma, Large B-Cell, Diffuse 62Recurrence 61Head and Neck Neoplasms 60Carcinoma, Renal Cell 59Brain Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Lymphoma, Non-Hodgkin 54Endometrial Neoplasms 54Leukemia, Lymphocytic, Chronic, B-Cell 53Hematologic Neoplasms 53Stomach Neoplasms 52Small Cell Lung Carcinoma 50Urinary Bladder Neoplasms 47

Interventions

fasudil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Alzheimer Disease × 90 days × Clear all
NCT06745583 2026-06-09

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Elixiron Immunotherapeutics Inc.

Phase 2 Recruiting
15 enrolled
Lymphoid

Neuroinflammatory Diseases, Alzheimer Disease, Lymphoma, Follicular, Neurodegenerative Diseases, Cognitive Dysfunction

NCT06362707 2026-05-04

FEAD

Helse Stavanger HF

Phase 2 Recruiting
200 enrolled
Lymphoid

Alzheimer Disease, Lymphoma, Follicular, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡